SlideShare a Scribd company logo
1 of 56
Aetiology, Spread,
Grading, Staging and
management of tumors
By
Dr Ankit Kumar
under guidance of
Dr Dharmraj Meena Sir
 Study of neoplastic diseases:
 ONCOS = tumor LOGOS = study
Neoplasm:
 Altered cell population characterized by
an excessive, non-useful proliferation
of cells that are unresponsive to normal
control mechanisms and to organizing
influences of adjacent tissue.
Neoplasm:
1. Malignant:
 Cancer cells that exhibit uncontrolled
proliferation and impair the function of
normal organs by local tissue invasion
and metastatic spread to distant
anatomic sites.
2. Benign:
 Composed of normal appearing cells
that do not invade locally or
metastasize to other sites
EPIDEMIOLOGY:



Overall cancer death rates shows
slow steady increase
Lower death rates during past
50yrs:
1. Stomach
2. Uterus
Increase death rates:
1. Lung
2. Pancreas
EPIDEMIOLOGY:
Cancer incidence by sites and sex:
Male Female
Lung 20% Breast 27%
Prostate 20% Colon & Rectum 16%
Colon & Rectum 14% Lung 11%
Urinary 10% Uterus 10%
Leukemia &
Lymphoma
8%
Leukemia &
Lymphoma
7%
Skin, pancreas
and oral
3-4%
Skin, pancreas
and oral
3-4%
EPIDEMIOLOGY:
Cancer death by sites and sex:
Male Female
Lung 36% Lung 20%
Colon & Rectum 11% Breast 18%
Prostate 10% Colon & Rectum 14%
Leukemia &
Lymphoma
9%
Leukemia &
Lymphoma
9%
Pancreas &
Urinary
5%
each
Pancreas & Ovary 5%
Urinary & Uterus
4%
each
 The most significant 5 yrs survival
rates are achieved in patients w/
cancer of skin, thyroid, cervix,
uterus and bladder; while the
lowest survival with pancreatic
cancer
ETIOLOGY:
Chemical carcinogens:
a. Hydrocarbons from coal tar = skin,
larynx & bronchial CA
b. Aromatic amines = urinary tract CA
c. Benzene = leukemia
d. Asbestos = mesothelioma
Physical carcinogens:
a. Ionizing radiations = bone cancer
 Multiple x-rays = skin/thyroid CA
b. Atomic bomb (Japan) = leukemia
ETIOLOGY:
Mechanical (chronic irritation):
 Marjolin’s ulcer = burn scar cancer
Infection:
 Parasitic:
 Schistosomas – Liver & bladder CA
 Viruses:




Hepatitis B – hepatocellular CA
Epstein-Barr virus – Burkitts lymphoma
Herpes simplex virus 2 – cervical CA
Aids
ETIOLOGY:
Precancerous conditions:
a. Leucoplakia
b. Actinic keratosis
c. Polyps of colon & rectum
d. Neurofibromas
e. Dysplasia of cervix, bronchial
f. Chronic ulcerative colitis
Hereditary factors:
 Familial polyposis – colonic CA
ETIOLOGY:
Oncogenes & Growth Factors:


RNA tumor viruses cause:
1. Carcinomas
2. Sarcoma
3. Leukemia
4. Lymphomas
Retrovirus have an enzyme that alters
genomic RNA resulting to abnormal
growth and differentiation of the cell.
Multi-factorial:
 Lung / breast CA
Breast Cancer Risk Factors
 Having first period before age12
 Not having children or having first children after
age 30
 Late age at menopause
 Family history of breast cancer
 Use of menopausal hormone therapy
 Exposure to radiation, especially at a young age
 Increrase body weight
 Alcohol intake,even low level of alcohol
Colorectal cancer Risk Factors
• Age- much more common after age 50
• Risk is higher for those with relatives who have
had colorectal cancer or polyps.
• A personal history of adenomatous polyp, if the
polyp is large,if there are many of them,or if any
of them shows dysplasia.
• A personal history of inflammatory bowel disease
• Long term tobacco use
• Excessive alcohol use(specially among men)
• Obesity
• Diets low in vegetables, fruits, and whole grains
• Diets hight in red meats(such as beef,pork or
liver) and processed meats(frying,grilling)
• Low level of physical activity
Stomach cancer Risk Factors
 Age – sharp increase in stomach cancer rates in
people over age 50
 Geography- world wide more common in japan,
china, south and central America.
 Helicobacter pylori infection
 Stomach lymphoma-MALT Lymphoma
 Obesity (causes gestric reflux)
 Lower intake of fruits and vegetables
 High intake of salt and salt-preserved foods
 Processed meat
 Physically inactive
 Previous stomach surgery
 Pernicious anemia
 Family history
CANCER BIOLOGY
1. Morphologic changes:





Rise from a single cell
Revert to more primitive cell types
Normal orderly tissue patterns are lost
or replaced by the random pilling up
of malignant cells w/o definite pattern
High index of mitoses
Invasion of adjacent structures
CANCER BIOLOGY
2. Biochemical changes:


Changes in DNA, RNA and chemical
architecture results to LOSS of
CONTACT INHIBITION to proliferation
and intercellular adhesiveness
Reversion of normal cellular
biochemistry to that of the embryonal
cells that produces EMBRYONAL subs.
(CEA, alpha fetoprotein)
CANCER BIOLOGY
Effector mechanism in tumor
immunity:
 Host provides a number of effector
mechs. that destroys the tumor:






Tumor-antigen-specific antibodies
Mononuclear phagocytes
Natural killer cells
Cytotoxic T lymphocytes
Neutrophils
K cells
CANCER BIOLOGY
Effector mechanism in tumor
immunity:
 Tumor Necrosis Factor (TNF):


Cytokines produced by monocytes,
machrophage, endothelial cells, large
granular lymphocytes and neutrophils
Properties:
a. Direct cytotoxicity for certain cells
b. Stimulation of procoagulant activity by
vascular endothelial cells
c. Induction of fever by direct effect on the
hypothalamic thermoregulatory center
CANCER PATHOLOGY
Classification of Neoplasm:
Carcinoma – arising from epithelial cells
Sarcoma – arise from connective tissue
and cells of mesenchymal origin
(fibrous, muscular, fatty, vascular &
skeletal).
CANCER PATHOLOGY
Grading of malignancy:
 Broders classified carcinoma into
4 grades according to:
1. Degree of differentiation
2. Appearance of cells, their nuclei and
the number of mitotic figures
Grade I
Grade IV
– least malignant
– most malignant
CANCER PATHOLOGY
Carcinoma in Situ:
Has cytologic characteristic of
malignant tumors but with no
detectable invasion into the
surrounding tissue or infiltration
into deeper cell layers
ROUTES OF SPREAD:
 Metastasis may entirely dominate
the clinical picture, while the
primary tumor remains latent and
asymptomatic
1. Direct extension
2. Lymphatic spread
 Common in epithelial
neoplasms of all types (except
for basal cell CA)
ROUTES OF SPREAD:
3. Vascular spread



Either thru the thoracic duct or by the
invasion of blood vessels
Capillaries are almost invaded, veins
invaded frequently but arteries rarely.
More common in sarcomas
4. Spread through serous cavities
 Peritoneal seedings (gastrointestinal CA)
CLINICAL MANIFESTATION:
Seven Danger Signals of Cancer
(Direct manifestation):
1. Change in bowel or bladder habits
2. A sore that does not heal
3. Unusual bleeding or discharge
4. Thickening or lump in breast or
elsewhere
5. Indigestion or difficult in swallowing
6. Obvious change in wart or mole
7. Hoarseness of voice.
CLINICAL MANIFESTATION:
Indirect or Systemic Manifestation:
1. Secondary to metastasis
 Cachexia
2. Secondary to none metastatic:
a. Ectopic production of known hormones
b. Secretion of unidentified, hormone like
substances
c. Toxic substances secreted from the tumor
d. Autoimmune – host is sensitized to an
antigen from the tumor
CLINICAL MANIFESTATION:
Signs of Expansile growth:
1. Obstruction
2. Destruction
Signs of Infiltrative Growth:
 Tumor infiltrates the nerves
1. Pain
2. Numbness
3. paralysis
CLINICAL MANIFESTATION:
Signs of Tumor necrosis (Bleeding &
Infection):



Tumor may become necrotic, ulcerate
and bleed
Fatigue and weakness in right colon
cancer is due to anemia
Inflammation caused by cecal CA can
mimic the clinical symptoms of acute
AP or cholecystitis.
Unknown primary tumors presenting
as metastases
DIAGNOSIS OF CANCER:
A. Clinical History:
1. Weight loss
2. Loss of Appetite
3. Bleeding or a discharge from any
body orifice or nipple
4. Sore that is slow to heal
DIAGNOSIS OF CANCER:
5. Persistent cough or wheeze
6. Change in voice
7. Difficulty of swallowing
8. Change in bowel habit
9. Growing lump in the skin, breast,
abdomen or muscle
DIAGNOSIS OF CANCER:
B. Physical Examination:


Palpable masses (movable, non-
movable)
LN enlargement
C. Laboratory Examination:


Blood examination
Radiological procedure:
 X-ray, esophagoram, Barium enema,
mammography, thyroid scan, CT scan,
MRI
DIAGNOSIS OF CANCER:
Biopsy:


o
To document presence of malignancy
Types:
1. Needle biopsy (cytological)
2. Incisional biopsy
3. Excisional biopsy
Rapid frozen biopsy / exfoliative
cytology (Pap smear)
NEEDLE BIOPSY
A needle biopsy is procedure to obtain a sample of
cells from the body for diagnose a medical condition
or disease or to assess the progress of a treatment
.
Common needle biopsy procedure include Fine
Needle aspiration and core needle biopsy.
Needle biopsy may be used to take tissue or fluid
samples from muscles, bones and other organs,
such as the liver or lung.
NEEDLE BIOPSY
Fine needle aspiration- This type of needle biopsy
uses a thin, hollow needle to draw cells from the
body.
Core needle biopsy- This type of needle biopsy
uses a wider needle then does FNAC. The needle
used during core needle biopsy is a hollow tube that
allows to extract a core of tissue.
Pathology report includes -
A description of the biopsy sample
A description of the cells
A pathologists diagnosis
Incisional & Excisional Biopsy
An Incisional Biopsy is a test to remove a piece of
tissue from a lesion or mass. The tissue is then
tested to find out what it is.
An excisional biopsy is a test in which the whole
lesion or mass is removed and tested.
The tissue sample is reviewed by a pathologist
and a report is written.
STAGING OF CANCER:
Most cancers are staged in five broad groups.
These are usually referred to with Roman
numerals. Other kinds, like blood cancers,
lymphoma and brain cancer have their owen
staging system.
Physical examination and several tests are used
to determine the clinical stage- an estimate of
how far the cancer has spread and helpfull in
treatment plan . These test may includes Blood
and other test and scans like MRI,CT,USG, PET
or nucler scan .
STAGING OF CANCER:
Clinical Staging of Cancer:
TNM:
Stage 0 = means there is no cancer , only
abnormal cells with the potential to become
cancer . Also called carcinoma in situ.
Stage I = cancer confined to it’s primary site
Stage II = more locally advanced disease
Stage III = metastasis to regional LN
Stage IV = metastasis to distant sites

STAGING OF CANCER:
TNM System- Short form of tumor, node and
metastasis.
Tumor(T)- T, followed by number from 0-4 tells
how large the tumor is, T0 means no
measureable tumor. The higher the number, the
bigger the tumor.
Node(N)- N, followed by number from 0-3 tells
us if the cancer has spread to the lymph node,N0
means lymph nodes are not involved. A higher
the number means the cancer is in more lymph
nodes.
STAGING OF CANCER:
Metastasis(M)- M, is followed by either 0 or 1. It
says if cancer has spread to organs and tissues in
other part of body. A 0 means it hasn’t, and a 1
means it has.
If a cancer is localized to one area of body, then
surgery or radiotherapy could be enough to
remove it completely. If a cancer has spread,
chemotherapy, harmone therapy or biological
therapies that circulate throughout the
bloodstream are required.
Staging of Carcinoma of the colon
Tumor Stage (T)
Tx – Can not be assess
T0 – No evidence of tumor
T1 – Tumor invades submucosa
T2 – Tumor invades muscularis propria
T3 – Tumor invades through muscularis propria in
to subserosa or nonpetritonealized pericolic or
perirectal tissue.
T4 – Tumor directly invades other organs or
structures and /or perforates visceral peritoneum
Staging of Carcinoma of the colon
Regional nodal metastasis(N)
Nx – Regional lymph node can not be assessed
N0 – No nodal metastasis
N1 – Metastasis in 1 to 3 pericolic or perirectal
nodes
N2 – Metastasis in 4 to more pericolic or perirectal
nodes
N3 – Metastasis in any node along course of a
named vascular trunk and /or metastasis to apical
nodes
Staging of Carcinoma of the colon
Distant metastasis(M)
Mx – Presence of distant metastasis cannot be
assessed
M0 – No distant metastasis
M1 – Distant metastasis
Staging of Carcinoma of the colon
AJCC DUKES TNM
0 Tis
I A T1-2N0M0
II B T3-4N0M0
III C AnyT,N1-3,M0
IV D AnyT,AnyN,M1
STAGING OF CANCER:
A. Post-surgical Resection Staging:

The extent of disease using all data available at the
time of surgery and on examination of a
completely resected specimen.
B. Re-treatment Staging:

Restaging is necessary for additional or secondary
definitive treatment after a (disease-free) interval
following 1st treatment.
C. Autopsy Staging:
 Used only when the cancer is 1st diagnosed at
autopsy.
CANCER TREATMENT:
1. Surgical resection
2. Radiation therapy
3. Chemotherapy


Surgery & radiation tx represents
treatment of cancers that remains
localized to it’s primary site or regional
LN.
Chemotherapy and Immunotherapy
– tx effective against tumor cells already
metastatic to distant organ sites.
CANCER TREATMENT:
GOALS of Therapy:
 Vary with extent of the cancer:
1. Localized w/o evidence of spread:
 Eradicate the cancer and CURE
THE PATIENT
2. Spread beyond the local site:
 Control patient’s symptoms and
to maintain maximum activity
for the longest possible period
of time.
CANCER TREATMENT:
CRITERIA of Incurability:
1. Distant metastasis (most common)
2. Evidence of extensive local
infiltration of adjacent organs or
structures


Pt’s general condition and the presence
of any co-existing disease must be
considered in planning therapy.
The PSYCHOLOGICAL makeup of the
patient and the patient’s life situation
must be considered.
CANCER TREATMENT:
SURGICAL RESECTION:
A. Surgical Curative Resection:
 Wide local resection:


Low grade malignancy
Basal cell CA of the skin
 Radical Local Resection:


High grade malignancy
En Bloc LN dissection for breast,
esophagus, gastric, colorectal CA
B. Surgical Palliative Resection:
1. To relieve symptoms
2. To prolong a useful comfortable life
3. Gastrojejunostomy, colostomy
CANCER TREATMENT:
RADIOTHERAPY:


Destroy tumor with preservation of
anatomic structures
Direct toxic effect to cells due to
ionization of water
CANCER TREATMENT:
CHEMOTHERAPY:
Antimetabolites:
Methotrexate & 5-FU
Alkylating agents:
cyclophosphamide
Ifosfamide
Chlorambucil
Melphalan
Busulfan
Carmustine, Lomustine
Dacarbazine, Procabazine
CANCER TREATMENT:
CHEMOTHERAPY:
Antibiotics:
Actinomycin D, Doxorubicin, Bleomycin
Vinca Alkaloids:
Vincristine & Vinblastine
CANCER TREATMENT:
IMMUNOTHERAPY:



Inhibit proliferation of cancer cells w/o
affecting function of normal cells
Stimulates the host to generate specific
immune response to its tumor-vaccine from
tumor cells
TUMOR SPECIFIC ANTISERUM:


Murine monoclonal antibodies
Immunotoxins
 None-specific immunotherapy=BCG vaccine
CANCER TREATMENT:
HIPEC (Hyperthermic Interperitonial
chemotherapy)– is a highly
concentrated, heated chemotherapy
treatment that is delivered directly to
the abdomen during surgery.
• Heating (41 to 43 degree
Celsius)the solution may also
improve the absorption of
chemotherapy
• The procedure treats tumors in the
abdomen ( peritoneal) lining that
stem from
colon,gastric,ovarian,appendix
tumors
CANCER TREATMENT:
TACE(Transarterial chemoembolization therapy)
is a localised method of administrating
chemotherapy directing to a liver tumor via a
catheter.
• TACE is most commonly used in the treatment
of hepatocellular carcinoma & selective
metastasis disease (most commonly from
colorectal carcinoma ) , it may also be used in
cholangiocarcinoma.
• It can be used as palliative treatment for a
patient with unresectable HCC or as a bridge
to a liver transplant.
CANCER TREATMENT:
TAE (Transarterial embolism) i.e.
without a chemotherapy agent added,
is also used.
This may be just as effective as TACE
PROGNOSIS:
DETERMINANTS:
1. Site of origin of primary tumor
2. Stage of the disease
3. Histologic features of the cancer
4. Host immune factors
5. Age of the patients
THANK YOU

More Related Content

What's hot (20)

Structure and Characteristics of Normal and Cancerous cells.pptx
Structure and Characteristics of Normal and Cancerous cells.pptxStructure and Characteristics of Normal and Cancerous cells.pptx
Structure and Characteristics of Normal and Cancerous cells.pptx
 
Cancer Staging
Cancer StagingCancer Staging
Cancer Staging
 
Oral cancers, Squamous Cell Carcinoma of Oral Cavity
 Oral cancers, Squamous Cell Carcinoma of Oral Cavity Oral cancers, Squamous Cell Carcinoma of Oral Cavity
Oral cancers, Squamous Cell Carcinoma of Oral Cavity
 
Biopsy
BiopsyBiopsy
Biopsy
 
Radiotherapy AND CHEMOTHERAPY
Radiotherapy AND CHEMOTHERAPYRadiotherapy AND CHEMOTHERAPY
Radiotherapy AND CHEMOTHERAPY
 
Cryptorchidism
CryptorchidismCryptorchidism
Cryptorchidism
 
Bone tumor
Bone tumorBone tumor
Bone tumor
 
Neoplasm
NeoplasmNeoplasm
Neoplasm
 
Wound and Wound healing
Wound and Wound healing Wound and Wound healing
Wound and Wound healing
 
Oral cancer
Oral cancerOral cancer
Oral cancer
 
Basal cell carcinoma
Basal cell carcinomaBasal cell carcinoma
Basal cell carcinoma
 
TNM classifiction.pptx
TNM classifiction.pptxTNM classifiction.pptx
TNM classifiction.pptx
 
Cancer of the oral cavity
Cancer of the oral cavityCancer of the oral cavity
Cancer of the oral cavity
 
Ovarian Cancer
Ovarian CancerOvarian Cancer
Ovarian Cancer
 
Odontogenic tumors
Odontogenic tumorsOdontogenic tumors
Odontogenic tumors
 
Cancer cell
Cancer cellCancer cell
Cancer cell
 
Precancerous lesions & conditions
Precancerous lesions & conditionsPrecancerous lesions & conditions
Precancerous lesions & conditions
 
Biopsy
BiopsyBiopsy
Biopsy
 
Metastasis
MetastasisMetastasis
Metastasis
 
Cancer treatment
Cancer treatment Cancer treatment
Cancer treatment
 

Similar to Tumor (20)

Surgical Oncology
Surgical OncologySurgical Oncology
Surgical Oncology
 
Cancer
Cancer Cancer
Cancer
 
Cancer
CancerCancer
Cancer
 
Cancer_updated
Cancer_updatedCancer_updated
Cancer_updated
 
Cancer things to know pptx
Cancer things to know pptxCancer things to know pptx
Cancer things to know pptx
 
Malignant disorders
Malignant disorders Malignant disorders
Malignant disorders
 
Cancer.pptx
Cancer.pptxCancer.pptx
Cancer.pptx
 
Surgical oncology
Surgical oncologySurgical oncology
Surgical oncology
 
neoplasm2. pptx
neoplasm2.                            pptxneoplasm2.                            pptx
neoplasm2. pptx
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
Nursing care of client with cancer
Nursing care of client with cancerNursing care of client with cancer
Nursing care of client with cancer
 
Cancer, Etiology, Classification and Pathophysiology
Cancer, Etiology, Classification and PathophysiologyCancer, Etiology, Classification and Pathophysiology
Cancer, Etiology, Classification and Pathophysiology
 
01 NEOPLASIA.pptx
01 NEOPLASIA.pptx01 NEOPLASIA.pptx
01 NEOPLASIA.pptx
 
Assignment on NEOPLASIA
Assignment on NEOPLASIA Assignment on NEOPLASIA
Assignment on NEOPLASIA
 
Neoplasia2003
Neoplasia2003Neoplasia2003
Neoplasia2003
 
Neoplasms.pptx
Neoplasms.pptxNeoplasms.pptx
Neoplasms.pptx
 
Cancer
CancerCancer
Cancer
 
Nursing Care of A patient with Cancer.ppt
Nursing Care of A patient with Cancer.pptNursing Care of A patient with Cancer.ppt
Nursing Care of A patient with Cancer.ppt
 
neoplastic disruptions alterations in cell function & differentiation pp
neoplastic disruptions   alterations in cell function & differentiation ppneoplastic disruptions   alterations in cell function & differentiation pp
neoplastic disruptions alterations in cell function & differentiation pp
 
Tumors
TumorsTumors
Tumors
 

Recently uploaded

ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for BeginnersSabitha Banu
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementmkooblal
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitolTechU
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfMr Bounab Samir
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxDr.Ibrahim Hassaan
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
MICROBIOLOGY biochemical test detailed.pptx
MICROBIOLOGY biochemical test detailed.pptxMICROBIOLOGY biochemical test detailed.pptx
MICROBIOLOGY biochemical test detailed.pptxabhijeetpadhi001
 

Recently uploaded (20)

ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for Beginners
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of management
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptx
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptx
 
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
MICROBIOLOGY biochemical test detailed.pptx
MICROBIOLOGY biochemical test detailed.pptxMICROBIOLOGY biochemical test detailed.pptx
MICROBIOLOGY biochemical test detailed.pptx
 

Tumor

  • 1. Aetiology, Spread, Grading, Staging and management of tumors By Dr Ankit Kumar under guidance of Dr Dharmraj Meena Sir
  • 2.  Study of neoplastic diseases:  ONCOS = tumor LOGOS = study Neoplasm:  Altered cell population characterized by an excessive, non-useful proliferation of cells that are unresponsive to normal control mechanisms and to organizing influences of adjacent tissue.
  • 3. Neoplasm: 1. Malignant:  Cancer cells that exhibit uncontrolled proliferation and impair the function of normal organs by local tissue invasion and metastatic spread to distant anatomic sites. 2. Benign:  Composed of normal appearing cells that do not invade locally or metastasize to other sites
  • 4. EPIDEMIOLOGY:    Overall cancer death rates shows slow steady increase Lower death rates during past 50yrs: 1. Stomach 2. Uterus Increase death rates: 1. Lung 2. Pancreas
  • 5. EPIDEMIOLOGY: Cancer incidence by sites and sex: Male Female Lung 20% Breast 27% Prostate 20% Colon & Rectum 16% Colon & Rectum 14% Lung 11% Urinary 10% Uterus 10% Leukemia & Lymphoma 8% Leukemia & Lymphoma 7% Skin, pancreas and oral 3-4% Skin, pancreas and oral 3-4%
  • 6. EPIDEMIOLOGY: Cancer death by sites and sex: Male Female Lung 36% Lung 20% Colon & Rectum 11% Breast 18% Prostate 10% Colon & Rectum 14% Leukemia & Lymphoma 9% Leukemia & Lymphoma 9% Pancreas & Urinary 5% each Pancreas & Ovary 5% Urinary & Uterus 4% each
  • 7.  The most significant 5 yrs survival rates are achieved in patients w/ cancer of skin, thyroid, cervix, uterus and bladder; while the lowest survival with pancreatic cancer
  • 8. ETIOLOGY: Chemical carcinogens: a. Hydrocarbons from coal tar = skin, larynx & bronchial CA b. Aromatic amines = urinary tract CA c. Benzene = leukemia d. Asbestos = mesothelioma Physical carcinogens: a. Ionizing radiations = bone cancer  Multiple x-rays = skin/thyroid CA b. Atomic bomb (Japan) = leukemia
  • 9. ETIOLOGY: Mechanical (chronic irritation):  Marjolin’s ulcer = burn scar cancer Infection:  Parasitic:  Schistosomas – Liver & bladder CA  Viruses:     Hepatitis B – hepatocellular CA Epstein-Barr virus – Burkitts lymphoma Herpes simplex virus 2 – cervical CA Aids
  • 10. ETIOLOGY: Precancerous conditions: a. Leucoplakia b. Actinic keratosis c. Polyps of colon & rectum d. Neurofibromas e. Dysplasia of cervix, bronchial f. Chronic ulcerative colitis Hereditary factors:  Familial polyposis – colonic CA
  • 11. ETIOLOGY: Oncogenes & Growth Factors:   RNA tumor viruses cause: 1. Carcinomas 2. Sarcoma 3. Leukemia 4. Lymphomas Retrovirus have an enzyme that alters genomic RNA resulting to abnormal growth and differentiation of the cell. Multi-factorial:  Lung / breast CA
  • 12. Breast Cancer Risk Factors  Having first period before age12  Not having children or having first children after age 30  Late age at menopause  Family history of breast cancer  Use of menopausal hormone therapy  Exposure to radiation, especially at a young age  Increrase body weight  Alcohol intake,even low level of alcohol
  • 13. Colorectal cancer Risk Factors • Age- much more common after age 50 • Risk is higher for those with relatives who have had colorectal cancer or polyps. • A personal history of adenomatous polyp, if the polyp is large,if there are many of them,or if any of them shows dysplasia. • A personal history of inflammatory bowel disease • Long term tobacco use • Excessive alcohol use(specially among men) • Obesity • Diets low in vegetables, fruits, and whole grains • Diets hight in red meats(such as beef,pork or liver) and processed meats(frying,grilling) • Low level of physical activity
  • 14. Stomach cancer Risk Factors  Age – sharp increase in stomach cancer rates in people over age 50  Geography- world wide more common in japan, china, south and central America.  Helicobacter pylori infection  Stomach lymphoma-MALT Lymphoma  Obesity (causes gestric reflux)  Lower intake of fruits and vegetables  High intake of salt and salt-preserved foods  Processed meat  Physically inactive  Previous stomach surgery  Pernicious anemia  Family history
  • 15. CANCER BIOLOGY 1. Morphologic changes:      Rise from a single cell Revert to more primitive cell types Normal orderly tissue patterns are lost or replaced by the random pilling up of malignant cells w/o definite pattern High index of mitoses Invasion of adjacent structures
  • 16. CANCER BIOLOGY 2. Biochemical changes:   Changes in DNA, RNA and chemical architecture results to LOSS of CONTACT INHIBITION to proliferation and intercellular adhesiveness Reversion of normal cellular biochemistry to that of the embryonal cells that produces EMBRYONAL subs. (CEA, alpha fetoprotein)
  • 17. CANCER BIOLOGY Effector mechanism in tumor immunity:  Host provides a number of effector mechs. that destroys the tumor:       Tumor-antigen-specific antibodies Mononuclear phagocytes Natural killer cells Cytotoxic T lymphocytes Neutrophils K cells
  • 18. CANCER BIOLOGY Effector mechanism in tumor immunity:  Tumor Necrosis Factor (TNF):   Cytokines produced by monocytes, machrophage, endothelial cells, large granular lymphocytes and neutrophils Properties: a. Direct cytotoxicity for certain cells b. Stimulation of procoagulant activity by vascular endothelial cells c. Induction of fever by direct effect on the hypothalamic thermoregulatory center
  • 19. CANCER PATHOLOGY Classification of Neoplasm: Carcinoma – arising from epithelial cells Sarcoma – arise from connective tissue and cells of mesenchymal origin (fibrous, muscular, fatty, vascular & skeletal).
  • 20. CANCER PATHOLOGY Grading of malignancy:  Broders classified carcinoma into 4 grades according to: 1. Degree of differentiation 2. Appearance of cells, their nuclei and the number of mitotic figures Grade I Grade IV – least malignant – most malignant
  • 21. CANCER PATHOLOGY Carcinoma in Situ: Has cytologic characteristic of malignant tumors but with no detectable invasion into the surrounding tissue or infiltration into deeper cell layers
  • 22. ROUTES OF SPREAD:  Metastasis may entirely dominate the clinical picture, while the primary tumor remains latent and asymptomatic 1. Direct extension 2. Lymphatic spread  Common in epithelial neoplasms of all types (except for basal cell CA)
  • 23. ROUTES OF SPREAD: 3. Vascular spread    Either thru the thoracic duct or by the invasion of blood vessels Capillaries are almost invaded, veins invaded frequently but arteries rarely. More common in sarcomas 4. Spread through serous cavities  Peritoneal seedings (gastrointestinal CA)
  • 24. CLINICAL MANIFESTATION: Seven Danger Signals of Cancer (Direct manifestation): 1. Change in bowel or bladder habits 2. A sore that does not heal 3. Unusual bleeding or discharge 4. Thickening or lump in breast or elsewhere 5. Indigestion or difficult in swallowing 6. Obvious change in wart or mole 7. Hoarseness of voice.
  • 25. CLINICAL MANIFESTATION: Indirect or Systemic Manifestation: 1. Secondary to metastasis  Cachexia 2. Secondary to none metastatic: a. Ectopic production of known hormones b. Secretion of unidentified, hormone like substances c. Toxic substances secreted from the tumor d. Autoimmune – host is sensitized to an antigen from the tumor
  • 26. CLINICAL MANIFESTATION: Signs of Expansile growth: 1. Obstruction 2. Destruction Signs of Infiltrative Growth:  Tumor infiltrates the nerves 1. Pain 2. Numbness 3. paralysis
  • 27. CLINICAL MANIFESTATION: Signs of Tumor necrosis (Bleeding & Infection):    Tumor may become necrotic, ulcerate and bleed Fatigue and weakness in right colon cancer is due to anemia Inflammation caused by cecal CA can mimic the clinical symptoms of acute AP or cholecystitis. Unknown primary tumors presenting as metastases
  • 28. DIAGNOSIS OF CANCER: A. Clinical History: 1. Weight loss 2. Loss of Appetite 3. Bleeding or a discharge from any body orifice or nipple 4. Sore that is slow to heal
  • 29. DIAGNOSIS OF CANCER: 5. Persistent cough or wheeze 6. Change in voice 7. Difficulty of swallowing 8. Change in bowel habit 9. Growing lump in the skin, breast, abdomen or muscle
  • 30. DIAGNOSIS OF CANCER: B. Physical Examination:   Palpable masses (movable, non- movable) LN enlargement C. Laboratory Examination:   Blood examination Radiological procedure:  X-ray, esophagoram, Barium enema, mammography, thyroid scan, CT scan, MRI
  • 31. DIAGNOSIS OF CANCER: Biopsy:   o To document presence of malignancy Types: 1. Needle biopsy (cytological) 2. Incisional biopsy 3. Excisional biopsy Rapid frozen biopsy / exfoliative cytology (Pap smear)
  • 32. NEEDLE BIOPSY A needle biopsy is procedure to obtain a sample of cells from the body for diagnose a medical condition or disease or to assess the progress of a treatment . Common needle biopsy procedure include Fine Needle aspiration and core needle biopsy. Needle biopsy may be used to take tissue or fluid samples from muscles, bones and other organs, such as the liver or lung.
  • 33. NEEDLE BIOPSY Fine needle aspiration- This type of needle biopsy uses a thin, hollow needle to draw cells from the body. Core needle biopsy- This type of needle biopsy uses a wider needle then does FNAC. The needle used during core needle biopsy is a hollow tube that allows to extract a core of tissue. Pathology report includes - A description of the biopsy sample A description of the cells A pathologists diagnosis
  • 34. Incisional & Excisional Biopsy An Incisional Biopsy is a test to remove a piece of tissue from a lesion or mass. The tissue is then tested to find out what it is. An excisional biopsy is a test in which the whole lesion or mass is removed and tested. The tissue sample is reviewed by a pathologist and a report is written.
  • 35. STAGING OF CANCER: Most cancers are staged in five broad groups. These are usually referred to with Roman numerals. Other kinds, like blood cancers, lymphoma and brain cancer have their owen staging system. Physical examination and several tests are used to determine the clinical stage- an estimate of how far the cancer has spread and helpfull in treatment plan . These test may includes Blood and other test and scans like MRI,CT,USG, PET or nucler scan .
  • 36. STAGING OF CANCER: Clinical Staging of Cancer: TNM: Stage 0 = means there is no cancer , only abnormal cells with the potential to become cancer . Also called carcinoma in situ. Stage I = cancer confined to it’s primary site Stage II = more locally advanced disease Stage III = metastasis to regional LN Stage IV = metastasis to distant sites 
  • 37. STAGING OF CANCER: TNM System- Short form of tumor, node and metastasis. Tumor(T)- T, followed by number from 0-4 tells how large the tumor is, T0 means no measureable tumor. The higher the number, the bigger the tumor. Node(N)- N, followed by number from 0-3 tells us if the cancer has spread to the lymph node,N0 means lymph nodes are not involved. A higher the number means the cancer is in more lymph nodes.
  • 38. STAGING OF CANCER: Metastasis(M)- M, is followed by either 0 or 1. It says if cancer has spread to organs and tissues in other part of body. A 0 means it hasn’t, and a 1 means it has. If a cancer is localized to one area of body, then surgery or radiotherapy could be enough to remove it completely. If a cancer has spread, chemotherapy, harmone therapy or biological therapies that circulate throughout the bloodstream are required.
  • 39. Staging of Carcinoma of the colon Tumor Stage (T) Tx – Can not be assess T0 – No evidence of tumor T1 – Tumor invades submucosa T2 – Tumor invades muscularis propria T3 – Tumor invades through muscularis propria in to subserosa or nonpetritonealized pericolic or perirectal tissue. T4 – Tumor directly invades other organs or structures and /or perforates visceral peritoneum
  • 40. Staging of Carcinoma of the colon Regional nodal metastasis(N) Nx – Regional lymph node can not be assessed N0 – No nodal metastasis N1 – Metastasis in 1 to 3 pericolic or perirectal nodes N2 – Metastasis in 4 to more pericolic or perirectal nodes N3 – Metastasis in any node along course of a named vascular trunk and /or metastasis to apical nodes
  • 41. Staging of Carcinoma of the colon Distant metastasis(M) Mx – Presence of distant metastasis cannot be assessed M0 – No distant metastasis M1 – Distant metastasis
  • 42. Staging of Carcinoma of the colon AJCC DUKES TNM 0 Tis I A T1-2N0M0 II B T3-4N0M0 III C AnyT,N1-3,M0 IV D AnyT,AnyN,M1
  • 43. STAGING OF CANCER: A. Post-surgical Resection Staging:  The extent of disease using all data available at the time of surgery and on examination of a completely resected specimen. B. Re-treatment Staging:  Restaging is necessary for additional or secondary definitive treatment after a (disease-free) interval following 1st treatment. C. Autopsy Staging:  Used only when the cancer is 1st diagnosed at autopsy.
  • 44. CANCER TREATMENT: 1. Surgical resection 2. Radiation therapy 3. Chemotherapy   Surgery & radiation tx represents treatment of cancers that remains localized to it’s primary site or regional LN. Chemotherapy and Immunotherapy – tx effective against tumor cells already metastatic to distant organ sites.
  • 45. CANCER TREATMENT: GOALS of Therapy:  Vary with extent of the cancer: 1. Localized w/o evidence of spread:  Eradicate the cancer and CURE THE PATIENT 2. Spread beyond the local site:  Control patient’s symptoms and to maintain maximum activity for the longest possible period of time.
  • 46. CANCER TREATMENT: CRITERIA of Incurability: 1. Distant metastasis (most common) 2. Evidence of extensive local infiltration of adjacent organs or structures   Pt’s general condition and the presence of any co-existing disease must be considered in planning therapy. The PSYCHOLOGICAL makeup of the patient and the patient’s life situation must be considered.
  • 47. CANCER TREATMENT: SURGICAL RESECTION: A. Surgical Curative Resection:  Wide local resection:   Low grade malignancy Basal cell CA of the skin  Radical Local Resection:   High grade malignancy En Bloc LN dissection for breast, esophagus, gastric, colorectal CA B. Surgical Palliative Resection: 1. To relieve symptoms 2. To prolong a useful comfortable life 3. Gastrojejunostomy, colostomy
  • 48. CANCER TREATMENT: RADIOTHERAPY:   Destroy tumor with preservation of anatomic structures Direct toxic effect to cells due to ionization of water
  • 49. CANCER TREATMENT: CHEMOTHERAPY: Antimetabolites: Methotrexate & 5-FU Alkylating agents: cyclophosphamide Ifosfamide Chlorambucil Melphalan Busulfan Carmustine, Lomustine Dacarbazine, Procabazine
  • 50. CANCER TREATMENT: CHEMOTHERAPY: Antibiotics: Actinomycin D, Doxorubicin, Bleomycin Vinca Alkaloids: Vincristine & Vinblastine
  • 51. CANCER TREATMENT: IMMUNOTHERAPY:    Inhibit proliferation of cancer cells w/o affecting function of normal cells Stimulates the host to generate specific immune response to its tumor-vaccine from tumor cells TUMOR SPECIFIC ANTISERUM:   Murine monoclonal antibodies Immunotoxins  None-specific immunotherapy=BCG vaccine
  • 52. CANCER TREATMENT: HIPEC (Hyperthermic Interperitonial chemotherapy)– is a highly concentrated, heated chemotherapy treatment that is delivered directly to the abdomen during surgery. • Heating (41 to 43 degree Celsius)the solution may also improve the absorption of chemotherapy • The procedure treats tumors in the abdomen ( peritoneal) lining that stem from colon,gastric,ovarian,appendix tumors
  • 53. CANCER TREATMENT: TACE(Transarterial chemoembolization therapy) is a localised method of administrating chemotherapy directing to a liver tumor via a catheter. • TACE is most commonly used in the treatment of hepatocellular carcinoma & selective metastasis disease (most commonly from colorectal carcinoma ) , it may also be used in cholangiocarcinoma. • It can be used as palliative treatment for a patient with unresectable HCC or as a bridge to a liver transplant.
  • 54. CANCER TREATMENT: TAE (Transarterial embolism) i.e. without a chemotherapy agent added, is also used. This may be just as effective as TACE
  • 55. PROGNOSIS: DETERMINANTS: 1. Site of origin of primary tumor 2. Stage of the disease 3. Histologic features of the cancer 4. Host immune factors 5. Age of the patients